Hyaluronate supports hESC‐cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction,Cell Proliferation

当前位置： X-MOL 学术 › Cell Prolif. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Hyaluronate supports hESC‐cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction
Cell Proliferation ( IF 5.9 ) Pub Date : 2020-10-27 , DOI: 10.1111/cpr.12942
Yuanqing Tan _{1,

2} , Lei Wang _{1,

2,

3} , Gang Chen ₁ , Wenjing Liu ₁ , Zhongwen Li _{1,

2,

3} , Yukai Wang _{1,

2,

3} , Liu Wang _{1,

2,

3,

4} , Wei Li _{1,

2,

3,

4} , Jun Wu _{1,

2,

3} , Jie Hao _{1,

2,

3}

Affiliation

Enormous progress has been made in cardiac regeneration using human embryonic stem cell‐derived cardiomyocyte (hESC‐CM) grafts in pre‐clinical trials. However, the rate of cell survival has remained very low due to anoikis after transplantation into the heart as single cells. Numerous solutions have been proposed to improve cell survival, and one of these strategies is to co‐transplant biocompatible materials or hydrogels with the hESC‐CMs.

中文翻译：

透明质酸支持 hESC-心肌细胞治疗急性心肌梗塞后的心脏再生

在临床前试验中，使用人胚胎干细胞衍生的心肌细胞 (hESC-CM) 移植物在心脏再生方面取得了巨大进展。然而，由于在作为单细胞移植到心脏后失巢凋亡，细胞存活率一直很低。已经提出了许多提高细胞存活率的解决方案，其中一种策略是将生物相容性材料或水凝胶与 hESC-CM 共同移植。

更新日期：2020-10-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11